Effect of Multidomain Intervention, Omega-3 Polyunsaturated Fatty Acids Supplementation or Their Combinaison on Cognitive Function in Non-Demented Older Adults According to Frail Status: Results from the MAPT Study

  • Maturin Tabue-Teguo
  • P. Barreto de Souza
  • C. Cantet Christelle
  • S. Andrieu
  • N. Simo
  • B. Fougère
  • J. F. Dartigues
  • B. Vellas
Article
  • 38 Downloads

Abstract

Background: Aim

The aim of this study was to explore whether multidomain intervention (MI) and Omega-3 Polyunsaturated Fatty Acids supplementation can modify the cognitive function on elderly according to frail status.

Method

Data are from a secondary exploratory analysis of the Multidomain Alzheimer Preventive Trial (MAPT), a French community-dwellers aged 70 or over reporting subjective memory complaints, but free from clinical dementia. The multidomain intervention consisted of 2 hours group sessions focusing on three domains (cognitive stimulation, physical activity, and nutrition) and a preventive consultation (at baseline, 12 months, and 24 months). For Omega-3 Polyunsaturated Fatty Acids supplementation, participants took two capsules of either placebo or polyunsaturated fatty acids daily. Linear mixed-model repeated-measures analyses were used including baseline, 6, 12, 24 and 36-month follow-up data to assess between-group differences in the change in cognitive tests over 36 months.

Results

The overall mean age of the MAPT study population was 75.25(±4.38). A tend toward significant differences in TMT-A were found for the effect of the multidomain intervention on the prefrail group compared to non-frail group. The MI and n3 PUFA program could not significantly have reduced cognitive function in a sample of pre-frailty elders.

Conclusion

This populationbased study in community-dwellers aged 70 years or over suggested that multidomain intervention and n3 PUFA supplementation have not significant effects on cognitive function change in frail older adults with memory complaints. The beneficial effect of multidomain intervention and n3 PUFA supplementation on cognitive function did not differ between frail and nonfrail participants.

Key words

Cohort study epidemiology frailty status multidomain intervention n3 PUFA supplementation 

References

  1. 1.
    Sink KM, Espeland MA, Castro CM, et al. Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. JAMA 2015;314:781–90. doi:10.1001/jama.2015.9617CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Albanese E, Shah H, Rudan I, et al. Dementia research priorities-1. Lancet Neurol 2017;16:180–1. doi:10.1016/S1474-4422(17)30006-6CrossRefPubMedGoogle Scholar
  3. 3.
    Andrieu S, Coley N, Lovestone S, et al. Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. Lancet Neurol 2015;14:926–44. doi:10.1016/S1474-4422(15)00153-2CrossRefPubMedGoogle Scholar
  4. 4.
    Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet Lond Engl 2015;385:2255–63. doi:10.1016/S0140-6736(15)60461-5CrossRefGoogle Scholar
  5. 5.
    Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a clusterrandomised controlled trial. Lancet Lond Engl 2016;388:797–805. doi:10.1016/S0140-6736(16)30950-3CrossRefGoogle Scholar
  6. 6.
    Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebocontrolled trial. Lancet Neurol 2017;16:377–89. doi:10.1016/S1474-4422(17)30040-6CrossRefPubMedGoogle Scholar
  7. 7.
    Trombetti A, Hars M, Hsu F, et al. Effet of physical activity on frailty: secondary analysis of a randomized controlled trail. Ann Intern Med. 2018 Jan 9. doi: 10.7326/M16-2011.Google Scholar
  8. 8.
    Fairhall N, Langron C, Sherrington C, et al. Treating frailty–a practical guide. BMC Med. 2011;9:83CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Morley JE. Frailty: diagnosis and management. J Nutr Health Aging 2011;15:667–70.CrossRefPubMedGoogle Scholar
  10. 10.
    Theou O, Brothers TD, Mitnitski A, et al. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. J Am Geriatr Soc 2013;61:1537–51. doi:10.1111/jgs.12420CrossRefPubMedGoogle Scholar
  11. 11.
    Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–156.CrossRefPubMedGoogle Scholar
  12. 12.
    Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ Can Med Assoc J J Assoc Medicale Can 2005;173:489–95. doi:10.1503/cmaj.050051CrossRefGoogle Scholar
  13. 13.
    Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet Lond Engl 2013;381:752–62. doi:10.1016/S0140-6736(12)62167-9CrossRefGoogle Scholar
  14. 14.
    Subra J, Gillette-Guyonnet S, Cesari M, et al. The integration of frailty into clinical practice: preliminary results from the Gérontopôle. J Nutr Health Aging 2012;16:714–20. doi:10.1007/s12603-012-0391-7CrossRefPubMedGoogle Scholar
  15. 15.
    Vellas B, Carrie I, Gillette-Guyonnet S, et al. MAPT Study: A multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prev Alzheimers Dis 2014;1:13–22.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37–49.CrossRefPubMedGoogle Scholar
  17. 17.
    Cardebat D, Doyon B, Puel M, et al. [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]. Acta Neurol Belg 1990;90:207–17.PubMedGoogle Scholar
  18. 18.
    Kaufman AS. Test Review: Wechsler, D. Manual for the Wechsler Adult Intelligence Scale, Revised. New York: Psychological Corporation, 1981. J Psychoeduc Assess 1983;1:309–13. doi:10.1177/073428298300100310CrossRefGoogle Scholar
  19. 19.
    Reitan R. Validity of the Trail Making Test as an indicator of brain damage. Percept Mot Skills. 1958:271–6.Google Scholar
  20. 20.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.CrossRefPubMedGoogle Scholar
  21. 21.
    Delrieu J, Andrieu S, Pahor M, et al. Neuropsychological Profile of “Cognitive Frailty” Subjects in MAPT Study. J Prev Alzheimers Dis 2016;3:151–9. doi:10.14283/ jpad.2016.94PubMedPubMedCentralGoogle Scholar

Copyright information

© Serdi and Springer-Verlag France SAS, part of Springer Nature 2018

Authors and Affiliations

  • Maturin Tabue-Teguo
    • 1
    • 2
    • 3
  • P. Barreto de Souza
    • 3
    • 4
  • C. Cantet Christelle
    • 3
    • 4
  • S. Andrieu
    • 3
    • 4
  • N. Simo
    • 5
  • B. Fougère
    • 3
    • 4
  • J. F. Dartigues
    • 2
  • B. Vellas
    • 3
    • 4
  1. 1.CHU de Pointe-à-Pitre (Guadeloupe)Université des Antilles (Guadeloupe), Centre de Recherche INSERM, U1219Bordeaux cedexFrance
  2. 2.INSERM UMR 1219, Equipe SEPIAUniversité de BordeauxBordeaux cedexFrance
  3. 3.GérontopôleCHU de ToulouseToulouseFrance
  4. 4.INSERM UMR 1027Université Toulouse 3ToulouseFrance
  5. 5.Pôle de Santé du VilleneuvoisVilleneuve/LotFrance

Personalised recommendations